Skip to main content
Top

28-09-2024 | Hodgkin Lymphoma | Original Article

Efficiency of PET-CT in Reducing the Usage of Radiotherapy in Childhood Hodgkin Lymphoma: A Single Center Experience

Authors: Goran Milosevic, Rodic Predrag, Nada Krstovski, Dejan Skoric, Alhayek Nabil, Milos Veljkovic, Jelena Lazić

Published in: Indian Journal of Hematology and Blood Transfusion

Login to get access

Abstract

Hodgkin Lymphoma is a complex malignancy with unique features, primarily affecting children and young adults. The disease’s sensitivity to radiation therapy and the young age of onset underscore the importance of optimizing treatment strategies to minimize both acute and long-term toxicities associated with radiotherapy. In light of these considerations, our study aimed to evaluate whether [18 F]FDG-PET/CT assessment at interim and end-of-treatment timings, in comparison to conventional CT scans, led to a decrease or increase in unnecessary patient exposure to radiotherapy. The study involved 61 pediatric patients diagnosed and treated for Hodgkin lymphoma at our institution between 2009 and 2022. Patients were categorized into two groups based on treatment protocols: Group 1 received conventional CT imaging protocols, while Group 2 received [18 F]FDG-PET/CT-based protocols. The results demonstrated that [18 F]FDG-PET/CT-based protocols led to a reduction in the frequency of radiotherapy compared to conventional CT imaging (32% vs. 52%). This statistically significant difference highlights the potential benefits of [18 F]FDG-PET/CT in guiding treatment decisions and reducing unnecessary radiation exposure. Our research re-emphasize the potential of [18 F]FDG-PET/CT as a valuable tool in the management of pediatric patients with Hodgkin lymphoma in terms of more precise diagnosis and reduction of unnecessary treatment and toxicities.
Literature
2.
go back to reference World Health Organization (2020) Estimated number of new cases in 2020, World, both sexes, all ages (excl. NMSC). Global Cancer Observatory. https://gco.iarc.fr. Accesed September 10, 2023 World Health Organization (2020) Estimated number of new cases in 2020, World, both sexes, all ages (excl. NMSC). Global Cancer Observatory. https://​gco.​iarc.​fr. Accesed September 10, 2023
3.
go back to reference Glaser SL, Jarrett RF (1996) The epidemiology of Hodgkin’s disease. Baillieres Clin Haematol 9(3):401–416CrossRefPubMed Glaser SL, Jarrett RF (1996) The epidemiology of Hodgkin’s disease. Baillieres Clin Haematol 9(3):401–416CrossRefPubMed
5.
go back to reference Kaseb H, Babiker HM, Hodgkin Lymphoma (2022) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan Kaseb H, Babiker HM, Hodgkin Lymphoma (2022) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan
6.
go back to reference Stein H et al (2017) In: Swerdlow SH et al (eds) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, pp 423–442 Stein H et al (2017) In: Swerdlow SH et al (eds) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, pp 423–442
7.
go back to reference Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s Disease staging classification. Cancer Res 31(11):1860–1861PubMed Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s Disease staging classification. Cancer Res 31(11):1860–1861PubMed
8.
go back to reference Gobbi PG, Ferreri AJM, Ponzoni M, Levis A (2013) Hodgkin lymphoma. Crit Rev Oncol Hematol 85(2):216–237CrossRefPubMed Gobbi PG, Ferreri AJM, Ponzoni M, Levis A (2013) Hodgkin lymphoma. Crit Rev Oncol Hematol 85(2):216–237CrossRefPubMed
9.
go back to reference Ansell SM, Hodgkin lymphoma (2020) A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol 95(8):978–989CrossRefPubMed Ansell SM, Hodgkin lymphoma (2020) A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol 95(8):978–989CrossRefPubMed
10.
go back to reference Kanoun S, Rossi C, Casasnovas O (2018) [18F]FDG-PET/CT in Hodgkin Lymphoma: current usefulness and perspectives. Cancers (Basel). 10(5) Kanoun S, Rossi C, Casasnovas O (2018) [18F]FDG-PET/CT in Hodgkin Lymphoma: current usefulness and perspectives. Cancers (Basel). 10(5)
11.
go back to reference Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78(3):206–212CrossRefPubMed Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78(3):206–212CrossRefPubMed
12.
go back to reference Kurch L, Hasenclever D, Kluge R et al (2019) Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: results of the GPOH-HD2002 trial. Pediatr Blood Cancer. 66(3) Kurch L, Hasenclever D, Kluge R et al (2019) Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: results of the GPOH-HD2002 trial. Pediatr Blood Cancer. 66(3)
13.
go back to reference Burnelli R, Rinieri S, Rondelli R et al (2018) Long-term results of the AIEOP MH’96 childhood Hodgkin’s lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. Leuk Lymphoma 59(11):2612–2621CrossRefPubMed Burnelli R, Rinieri S, Rondelli R et al (2018) Long-term results of the AIEOP MH’96 childhood Hodgkin’s lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. Leuk Lymphoma 59(11):2612–2621CrossRefPubMed
14.
go back to reference Mauz-Körholz C, Landman-Parker J, Balwierz W et al (2022) Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 23(1):125–137CrossRefPubMedPubMedCentral Mauz-Körholz C, Landman-Parker J, Balwierz W et al (2022) Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 23(1):125–137CrossRefPubMedPubMedCentral
15.
go back to reference Iyer VK (2013) Pediatric Lymphoma diagnosis: role of FNAC, Biopsy, immunohistochemistry and Molecular Diagnostics. Indian J Pediatr 80(9):756–763CrossRefPubMed Iyer VK (2013) Pediatric Lymphoma diagnosis: role of FNAC, Biopsy, immunohistochemistry and Molecular Diagnostics. Indian J Pediatr 80(9):756–763CrossRefPubMed
16.
go back to reference McCarten KM, Nadel HR, Shulkin BL, Cho SY (2019) Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-hodgkin lymphoma. Pediatr Radiol 49(11):1545–1564CrossRefPubMed McCarten KM, Nadel HR, Shulkin BL, Cho SY (2019) Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-hodgkin lymphoma. Pediatr Radiol 49(11):1545–1564CrossRefPubMed
17.
go back to reference Kasamon YL, Jones RJ, Wahl RL (2007) Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48(Suppl 1):19S–27SPubMed Kasamon YL, Jones RJ, Wahl RL (2007) Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48(Suppl 1):19S–27SPubMed
18.
go back to reference Jerusalem G, Beguin Y, Fassotte MF et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94(2):429–433CrossRefPubMed Jerusalem G, Beguin Y, Fassotte MF et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94(2):429–433CrossRefPubMed
19.
go back to reference Cheng G, Servaes S, Alavi A, Zhuang H (2008) FDG PET and PET/CT in the management of Pediatric Lymphoma patients. PET Clin 3(4):621–634CrossRefPubMed Cheng G, Servaes S, Alavi A, Zhuang H (2008) FDG PET and PET/CT in the management of Pediatric Lymphoma patients. PET Clin 3(4):621–634CrossRefPubMed
20.
go back to reference Elstrom RL, Leonard JP, Coleman M, Brown RKJ (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10):1770–1773CrossRefPubMedPubMedCentral Elstrom RL, Leonard JP, Coleman M, Brown RKJ (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10):1770–1773CrossRefPubMedPubMedCentral
21.
go back to reference Raanani P, Shasha Y, Perry C et al (2006) Is CT scan still necessary for staging in Hodgkin and non-hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17(1):117–122CrossRefPubMed Raanani P, Shasha Y, Perry C et al (2006) Is CT scan still necessary for staging in Hodgkin and non-hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17(1):117–122CrossRefPubMed
22.
go back to reference Hutchings M, Loft A, Hansen M et al (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91(4):482–489PubMed Hutchings M, Loft A, Hansen M et al (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91(4):482–489PubMed
23.
go back to reference Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86(12):897–903CrossRefPubMed Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86(12):897–903CrossRefPubMed
24.
go back to reference Engert A, Haverkamp H, Kobe C et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799CrossRefPubMed Engert A, Haverkamp H, Kobe C et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799CrossRefPubMed
25.
go back to reference Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and Response Assessment of Hodgkin and Non-hodgkin Lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3067CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and Response Assessment of Hodgkin and Non-hodgkin Lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3067CrossRefPubMedPubMedCentral
26.
go back to reference Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 32(27):3048–3058 Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 32(27):3048–3058
27.
go back to reference Totadri S, Radhakrishnan V, Ganesan TS et al (2018) Can Radiotherapy be omitted in children with Hodgkin Lymphoma who achieve metabolic remission on Interim Positron Emission Tomography? Experience of a Tertiary Care Cancer Referral Center. J Glob Oncol. (4):1–7 Totadri S, Radhakrishnan V, Ganesan TS et al (2018) Can Radiotherapy be omitted in children with Hodgkin Lymphoma who achieve metabolic remission on Interim Positron Emission Tomography? Experience of a Tertiary Care Cancer Referral Center. J Glob Oncol. (4):1–7
28.
go back to reference Palayullakandi A, Trehan A, Jain R et al (2022) Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting. Pediatr Hematol Oncol 39(7):587–599CrossRefPubMed Palayullakandi A, Trehan A, Jain R et al (2022) Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting. Pediatr Hematol Oncol 39(7):587–599CrossRefPubMed
29.
go back to reference Triumbari EKA, Gatta R, Maiolo E et al (2023) Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s lymphoma: the predictive role of the Largest and the hottest lesions. Diagnostics 13(8):1391CrossRefPubMedPubMedCentral Triumbari EKA, Gatta R, Maiolo E et al (2023) Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s lymphoma: the predictive role of the Largest and the hottest lesions. Diagnostics 13(8):1391CrossRefPubMedPubMedCentral
30.
go back to reference El-Saban Kamalnm (2022) K. Role of 18F-FDG-PET/CT in assessment of pediatric Hodgkin’s lymphoma. Q J Nuclear Med Mol Imaging. 65(4) El-Saban Kamalnm (2022) K. Role of 18F-FDG-PET/CT in assessment of pediatric Hodgkin’s lymphoma. Q J Nuclear Med Mol Imaging. 65(4)
31.
go back to reference Kalra M, Bakhshi S, Singh M et al (2023) Response assessment by positron emission tomography-computed tomography as compared with contrast-enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low- and middle-income countries. Pediatr Blood Cancer 70(2):e30091CrossRefPubMed Kalra M, Bakhshi S, Singh M et al (2023) Response assessment by positron emission tomography-computed tomography as compared with contrast-enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low- and middle-income countries. Pediatr Blood Cancer 70(2):e30091CrossRefPubMed
Metadata
Title
Efficiency of PET-CT in Reducing the Usage of Radiotherapy in Childhood Hodgkin Lymphoma: A Single Center Experience
Authors
Goran Milosevic
Rodic Predrag
Nada Krstovski
Dejan Skoric
Alhayek Nabil
Milos Veljkovic
Jelena Lazić
Publication date
28-09-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01878-9

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now